| In millions, except per share items | Jun-30-22 | Jun-30-21 | Jun-30-20 | Jun-30-19 | Jun-30-18 | Jun-30-17 | Jun-30-16 | Jun-30-15 |
| | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F |
| Revenue | | | | | | | | |
| Research & development | | | | | | | | |
| Manufacturing commercialization | -30.8 | -32.7 | -25.3 | -15.4 | -5.5 | -12.1 | -29.8 | |
| Management and administration | -27.2 | -30.9 | -25.6 | -21.6 | -21.9 | -23.0 | -22.5 | |
| Fair value remeasurement of contingent consideration | 0.9 | 18.7 | 1.4 | -6.3 | 10.5 | -0.1 | 28.1 | |
| Fair value remeasurement of warrant liability | 5.9 | | | | | | | |
| |
| Other operating income and expenses | | | | | | | | |
| Finance costs | | | | | | | | |
| Loss before income tax | | | | | | | | |
| Income tax benefit/(expense) | | | | | | | | |
| Loss attributable to the owners of Mesoblast Limited | | | | | | | | |
| Losses per share from continuing operations attributable to the ordinary equity holders of the Group: | | | | | | | | |
| Basic - losses per share | | | | | | | | |
| Diluted - losses per share | | | | | | | | |